Adding lipoprotein(a) levels to the GRACE score to predict prognosis in patients with non-ST elevation acute coronary syndrome

Kardiologia Polska

Volumn 71, Issue 7, 2013, Pages 695-701

  Guler, Ekrem ^a   Gecmen, Cetin ^b   Guler, Gamze Babur ^c   Karaca, Oguz ^a   Agus, Hicaz Zencirkiran ^b   Gunes, Haci Murat ^b   Batgerel, Ulankhuu ^b   Elveran, Ali ^b   Esen, Ali Metin ^b  

^a ISTANBUL MEDIPOL UNIVERSITY   (Turkey)

^b KOSUYOLU HEART AND RESEARCH HOSPITAL   (Turkey)

^c Cardiology Clinic   (Turkey)

Author keywords

Acute coronary syndromes; GRACE risk score; Lipoprotein(a)

Indexed keywords

CREATININE; HEMOGLOBIN; LIPOPROTEIN A;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; FEMALE; FOLLOW UP; GRACE SCORING SYSTEM; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PREDICTIVE VALUE; PROGNOSIS; SCORING SYSTEM;

EID: 84880795615     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: 10.5603/KP.2013.0156     Document Type: Article

References (25)

1. Rosamond W, Flegal K, Furie K et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2008; 117: e25-e146.
2. Tello-Montoliu A, Marin F, Rolda'n V et al. Multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels. J Intern Med, 2007; 262: 651-658.
3. Granger CB, Goldberg RJ, Dabbous OH et al. The Global Registry of Acute Coronary Events Investigators. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med, 2003; 163: 2345-2353.
4. Eagle KA, Lim MJ, Dabbous OH et al. The GRACE Investigators. A validated prediction model for all forms of acute coronary syndrome. Estimating the risk of 6-month post-discharge death in an international registry. JAMA, 2004; 291: 2727-2733.
5. Fox KAA, Dabbous OH, Goldberg RJ et al. The GRACE Investigators. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ, 2006; 333: 1091.
6. Schiele F, Meneveau N, Seronde MF et al. C-reactive protein improves risk prediction in patients with acute coronary syndromes. Eur Heart J, 2010; 31: 290-297.
7. Ang DS, Wei L, Kao MP et al. A comparison between B-type natriuretic peptide, Global Registry of Acute Coronary Events (GRACE) score and their combination in ACS risk stratification. Heart, 2009; 95: 1836-1842.
8. Erqou S, Kaptoge S, Perry PL et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA, 2009; 302: 412-423.
9. Jackson R, Scragg R, Marshall R et al. Changes in serum lipid concentrations during first 24 hours after myocardial infarction. Br Med J (Clin Res Ed), 1987; 294: 1588-1589.
10. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd Ed. John Wiley & Sons Inc., New York 2000.
11. Kleinbaum DG. Logistic regression a self learning text. Springer-Verlag New York Inc. 1994.
12. Fox KA, Carruthers KF, Dunbar DR et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J, 2010; 31: 2755-2764.
13. Utermann G. Lipoprotein(a). In: Scriver CR, Beaudet AL, Sly WS, Valle D eds. The metabolic and molecular bases of inherited disease. 8th Ed. McGraw-Hill, New York 2001: 2753-2787.
14. Berg K. A new serumtype system in man-The Lp system. Acta Pathol Microbiol Scand. 1963,59; 369-382
15. Beisiegel U, Niendorf A, Wolf K et al. Liporotein (a) in the arterial wall. Eur Heart J, 1990; 11 (suppl. E): 174-183.
16. Marcovina SM, Koschinsky ML. Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol, 2003; 14: 361-366.
17. Tsimikas S, Brilakis ES, Miller ER et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med, 2005; 353: 46-57.
18. Peña-Díaz A, Izaguirre-Avila R, Anglés-Cano E. Lipoprotein Lp(a) and atherothrombotic disease. Arch Med Res, 2000; 31: 353-359.
19. Frohlich J, Dobíasova M, Adler L et al. Gender differences in plasma levels of lipoprotein(a) in patients with angiographically proven coronary artery disease. Physiol Res, 2004; 53: 481-486.
20. Lima LM, Carvalho MG, Loures-Vale AA et al. Increased serum levels of lipoprotein(a) correlated with the severity of coronary artery disease in patients submitted to angiography. Arq Bras Cardiol, 2006; 87: 260-266.
21. Cho JY, Jeong MH, Ahn Y et al. High lipoprotein(a) levels are associated with long-term adverse outcomes in acute myocardial infarction patients in high Killip classes Korean. Circ J, 2010; 40: 491-498.
22. Al-Mallah MH, Hatahet H, Cavalcante JL et al. Low admission LDL-cholesterol is associated with increased 3-year all-cause mortality in patients with non ST segment elevation myocardial infarction. Cardiol J, 2009; 16: 227-233.
23. Nordestgaard BG, Chapman MJ, Ray K et al. for the European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J, 2010; 31: 2844-2853.
24. Maeda S, Abe A, Seishima M et al. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis, 1989; 78: 145-150.
25. Noma A, Abe A, Maeda S et al. Lp(a): an acute-phase reactant Chemistry Physics Lipids, 1994; 67-68: 411-417.